此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

裸盖菇素是否会改变遗忘性轻度认知障碍的突触密度

2026年9月30日 更新者:Philip Gerretsen、Centre for Addiction and Mental Health

裸盖菇素是否会改变遗忘性轻度认知障碍患者大脑中的突触密度

The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants with amnestic Mild Cognitive Impairment (aMCI) and healthy participants. The investigators hypothesize that SVD levels in the brain will be higher following the ingestion of psilocybin in comparison to placebo, and that increases in SVD will be associated with improvements in cognition.

10 participants (6 with aMCI, and 4 sex and age matched healthy volunteers) will:

  • Be randomized to receive either:

    1. Two 25 mg macrodoses of psilocybin separated by 1 week.
    2. Two placebo doses separated by 1 week.
  • Receive a baseline 18F-SynVesT-1 PET scan, clinical, and neuropsychological assessments.

  • Receive a 18F-SynVesT-1 PET scan one week after the last dose of treatment.

  • Depending on available funds, receive a third PET scan at any time within 4 weeks of the screening visit to quantify tauopathy with the [18F]T807 radiotracer.

  • Receive clinical and neuropsychological testing 1, 4, and 12 weeks after the last treatment.

Researchers will compare placebo vs. experimental groups to see if psilocybin will increase SVD, and if increases in SVD are associated with cognitive improvements.

研究概览

详细说明

The proposed study will investigate the effects of on synaptic vesicular density (SVD) levels as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, and cognition (i.e., global cognition, executive function, and memory domains) in amnestic Mild Cognitive Impairment (aMCI) and healthy participants. Participants will be randomized to receive either two 25mg doses of psilocybin separated by one week, or two placebo doses separated by one week. Brain scans, clinical, and cognitive assessments will be conducted one week before, and one week, four weeks, and 12 weeks post dosing.

研究类型

介入性

注册 (实际的)

10

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M5T 1R8
        • Centre for Addiction and Mental Health

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 至 75年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria

The aMCI participant must meet all of the inclusion criteria to be eligible for this clinical trial:

  1. Male or female participants of any race or ethnicity
  2. Inpatients or outpatients 60 to 75 years of age (on day of randomization)
  3. Diagnosis of MCI based on DSM 5 diagnostic criteria of Minor Neurocognitive Disorder
  4. Categorization of episodic memory impairment based on scores ≥ 1.0 SD lower on any of the following measures in comparison to normative data i. Logical Memory Test, ii. California Verbal Learning Test, iii. Brief Visual Memory Test
  5. Non-smoker/Non-nicotine user
  6. Montreal Cognitive Assessment (MoCA) score = < 26 and MMSE score > = 24
  7. Capable of consenting to participate in the research study
  8. On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
  9. Availability of a study partner who has regular contact with the participant
  10. Ability to read and communicate in English (with corrected vision and hearing, if needed)

The Healthy Control participant must meet all of the inclusion criteria to be eligible for this clinical trial:

  1. Male or female participants of any race or ethnicity
  2. 60 to 75 years of age (on day of randomization)
  3. Does not meet SCID-5 criteria for Mild Neurocognitive Disorder, Alzheimer's disease, or other major neurocognitive disorder
  4. Non-smoker/Non-nicotine user
  5. Capable of consenting to participate in the research study
  6. On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
  7. Availability of a study partner who has regular contact with the participant
  8. Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this clinical trial:

  1. Unwilling or incapable to consent to the study
  2. Unstable medical or any concomitant major medical or neurological illness, including presence of a relative or absolute contraindication to psilocybin, i.e. a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment.
  3. History of head trauma resulting in loss of consciousness > 30 minutes that required medical attention.
  4. DSM-5 diagnosis, with active symptoms in the last three months, of major depression; lifetime diagnosis of bipolar disorder; intellectual disability; Alzheimer's Disease; or a psychotic disorder
  5. DSM-5 substance dependence (except caffeine) within 12 months of entering the study
  6. Anticonvulsant, antidepressant, antipsychotic, mood stabilizer, opioid, or benzodiazepine use
  7. Use of serotonergic psychedelic drugs within the past 10 years
  8. Positive urine drug screen at the screening visit
  9. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks
  10. Acute suicidal or homicidal ideation
  11. Receiving treatment with medications such as levetiracetam that blocks SV2a binding, and/or inability to discontinue the following medications before study drug dosing: inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT)1A9 and (UGT)1A10, and ALDH inhibitors and alcohol dehydrogenase (ADH) inhibitors.
  12. Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines
  13. Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)
  14. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia)
  15. Female with childbearing potential*, pregnancy (as confirmed by a negative pregnancy test) or breastfeeding
  16. Active gender affirming hormonal treatment
  17. Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I or II disorder as determined by the family medical history form and discussions with the participant.
  18. Allergies to hydroxypropyl methylcellulose *A woman/female or person who is not of childbearing potential is considered to be postmenopausal after at least 12 months without menstruation. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Females/people of childbearing potential are those who have experienced menarche and do not meet the criteria for women not of childbearing potential.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Amnestic Mild Cognitive Impairment Participants Receiving Psilocybin

Receiving 2 doses of 25mg of psilocybin separated by 1 week.

2 macrodoses of 25mg separated by one week.

实验性的:Healthy Participants Receiving Psilocybin

Receiving 2 doses of 25mg of psilocybin separated by 1 week.

2 macrodoses of 25mg separated by one week.

安慰剂比较:Amnestic Mild Cognitive Impairment Participants Receiving Placebo

Receiving 2 doses of placebo separated by 1 week.

2 doses of placebo separated by one week.

安慰剂比较:Healthy Participants Receiving Placebo

Receiving 2 doses of placebo separated by 1 week.

2 doses of placebo separated by one week.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Synaptic Vesicular Density
大体时间:3 years

Synaptic vesicular density will be assessed with PET imaging by measuring the volume of distribution (i.e., defined as the ratio of the radioligand concentration in tissue target region (CT, kBq·cm-3) to that in plasma (CP, kBq·mL-1) at equilibrium) of the [18F]SynVesT-1 radioligand in the cortical and subcortical gray matter regions in the whole brain and more specifically, the hippocampus and dorsolateral prefrontal cortex.

3 years

次要结果测量

结果测量
措施说明
大体时间
Global Cognition
大体时间:3 years

The results of the neuropsychological battery will be combined to a global cognition composite score as a Z-score, the change of which will be a secondary outcome measure. Z-scores will be comprised of the Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure, and will be calculated based on the performance of the equated comparison group. Each domain will contribute equally to the global cognition composite score.

3 years
Memory
大体时间:3 years

A memory composite Z-score will be generated using the performance on the following individual tests: Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score.

3 years
Executive Function
大体时间:3 years

An executive function composite Z-score will be generated using the performance on the following individual tests: Trail Making Test Part B, Wisconsin Card Sorting Test, Stroop Neuropsychological Screening, and the Executive Interview. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score.

3 years

其他结果措施

结果测量
措施说明
大体时间
Exploratory Cognitive Outcomes
大体时间:3 years

If individual cognitive test scores are significantly different between groups, the mean difference of the individual test scores (i.e., Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure) will be analyzed separately as exploratory outcomes.

3 years
Exploratory Primary and Secondary Outcomes
大体时间:3 years

Primary and secondary outcomes will be compared between aMCI and healthy control groups.

The means of the primary outcome (i.e., volume of distribution) and secondary outcomes (i.e., cognitive composite Z-scores: global cognition, memory, and executive function) will be compared between aMCI and healthy control groups.

3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Philip Gerretsen, MD, PhD、Centre for Addiction and Mental Health

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月27日

初级完成 (实际的)

2026年2月19日

研究完成 (实际的)

2026年2月19日

研究注册日期

首次提交

2023年8月1日

首先提交符合 QC 标准的

2023年9月14日

首次发布 (实际的)

2023年9月18日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅